PHASE II TRIAL OF FOLFOX6, BEVACIZUMAB AND CETUXIMAB IN PATIENTS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：探讨FOLFOX 6、贝伐单抗和西妥昔单抗联合治疗晚期结直肠癌的安全性、可行性、疗效和生存率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine the safety, feasibility of administration, response and survival rates among patients with advanced colorectal cancer treated with the combination of drugs, Folfox6, Bevacizumab and Cetuximab.